A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

No Carolina / New York

MC-Rx Formalizes Pharmacy Benefit Coverage for Theranica’s Nerivio®, Providing Millions of Covered Members Access to the Novel Drug-Free Migraine Therapeutic

Agreement Simplifies and Accelerates Patient Access to Effective, Low Side Effect Drug Free Therapy for Acute Treatment of Migraine

Theranica, a prescribed digital therapeutics company developing advanced electroceuticals for migraine and other pain conditions, today announced it has signed an agreement with pharmacy benefit manager (PBM) MC-Rx, which places Theranica’s flagship Nerivio® device for acute treatment of migraine under MC-Rx’s Pharmacy Benefit formulary.

“MC-Rx continuously expands member access of innovative and cost-effective healthcare therapies, and this agreement with Theranica is a wonderful example of that,” said Roger Burgess, Chairman and CEO of MC-Rx. “Nerivio is a proven, science-based, drug-free migraine treatment that is already helping tens of thousands across the U.S. We are committed to facilitating our covered members’ access to a wide spectrum of treatment options for those suffering with this condition.”

The Pharmacy Benefit formulary designation by MC-Rx, which serves millions of members across the U.S., means migraine sufferers seeking digital therapeutic product treatment will now have a clear path for reimbursement when they are prescribed Nerivio by their healthcare providers.

Lindsay Videnieks, Executive Director of the Headache and Migraine Policy Forum, a not-for-profit organization dedicated to advancing public policies and practices to promote accelerated innovation and improved access to treatments for persons living with headache disorders and migraine, commented: “It is highly important to expand the access of people living with migraine to innovative FDA-cleared treatments that can help improve their quality of life. Neuromodulation devices are an essential element in the toolbox available for providers and patients, and health insurance companies should follow MC-Rx, as well as the VA, in reimbursing these prescribed treatments for people with migraine.”

Nerivio, a drug-free Remote Electrical Neuromodulation (REN) device for the acute treatment of migraine in patients 12 years and older, delivers electrical waveforms to nerve fibers at the upper arm to trigger Conditioned Pain Modulation in the central neural system, activating the body’s endogenous analgesic mechanism. Nerivio was recently included in the 2021 American Headache Society Consensus Statement for treating migraine.  

“In MC-Rx, Theranica has found a likeminded partner, with both companies believing strongly in the importance of simplifying and accelerating patient access to innovative and cost-effective non-drug therapies like Nerivio,” said Alon Ironi, Co-Founder and CEO of Theranica. “This is excellent news for people with migraine covered by benefit plans managed by MC-Rx living with migraine, as well as for the healthcare providers treating them, who can now prescribe Nerivio without hesitation.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The study is designed to assess the clinical utility and workflow benefits of Swoop® system images acquired at infusion centers and clinics to help physicians detect amyloid-related imaging abnormalities (ARIA) in Alzheimer’s patients receiving amyloid-targeting therapy at the times specified in the labeling (before the fifth, seventh, and fourteenth infusions).
“Tom and I have more than 50 years of experience,” Harp adds. “The decision to found Polymer Medical was done after careful consideration of the landscape and market opportunity; we will raise the level of competition and quality for customers.” Polymer Medical is located in a newly refurbished plant is at 168 Thorn Ave., Orchard Park, N.Y.
The RWE Program will expand Summus Laser's Class IV Laser Therapy research to generate validated and statistically significant datasets that will be used to enhance patient care, outcomes, and to further product innovations.
Details of the session: Polaroid Therapeutics & Avery Dennison Medical: How the power of partnership brings a novel approach to antimicrobial wound dressings.
SABIC advises the project was initiated together with the dialysis department at Jessa Hospital, one of the largest non-university medical cluster in the Limburg region of Flanders, Belgium.

By using this website you agree to accept Medical Device News Magazine Privacy Policy